Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies

NCT05411133 is registered in ClinicalTrials.gov with Arbele Pty Ltd as lead sponsor.

NCT NCT05411133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05411133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies
Lead sponsor
Arbele Pty Ltd
Phase
Phase 1
Overall status
Completed
Start date
May 30, 2022
Completion date
July 23, 2025
Enrollment
33 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, colorectal adenocarcinoma, esophageal adenocarcinoma, gastric cancer, gastroesophageal junction, gastrointestinal cancer, gastrointestinal neuroendocrine tumors, liver cancer, pancreatic cancer